CNTX Key Statistics, Chart & Performance
The current stock price of CNTX is 1.47 USD. In the past month the price increased by 38.68%. In the past year, price increased by 17.6%.
CNTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.87 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.94 | 498.60B | ||
| MRK | MERCK & CO. INC. | 11.95 | 261.26B | ||
| PFE | PFIZER INC | 7.78 | 141.57B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.22 | 109.81B | ||
| ZTS | ZOETIS INC | 19.85 | 55.45B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 22.30B | ||
| VTRS | VIATRIS INC | 5.34 | 14.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.57 | 11.24B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.21B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.58B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.42B |
Related stock screener links
About CNTX
Company Profile
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2021-10-20. The company is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
Company Info
CONTEXT THERAPEUTICS INC
2001 Market Street, Suite 3915 Unit #15
PHILADELPHIA PENNSYLVANIA US
Employees: 12
Phone: 12672257416
CONTEXT THERAPEUTICS INC / CNTX FAQ
Can you describe the business of CONTEXT THERAPEUTICS INC?
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 12 full-time employees. The company went IPO on 2021-10-20. The company is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
What is the stock price of CONTEXT THERAPEUTICS INC today?
The current stock price of CNTX is 1.47 USD. The price increased by 13.08% in the last trading session.
Does CONTEXT THERAPEUTICS INC pay dividends?
CNTX does not pay a dividend.
What is the ChartMill rating of CONTEXT THERAPEUTICS INC stock?
CNTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does CONTEXT THERAPEUTICS INC have?
CONTEXT THERAPEUTICS INC (CNTX) currently has 12 employees.
What is CONTEXT THERAPEUTICS INC worth?
CONTEXT THERAPEUTICS INC (CNTX) has a market capitalization of 135.06M USD. This makes CNTX a Micro Cap stock.
Can you provide the upcoming earnings date for CONTEXT THERAPEUTICS INC?
CONTEXT THERAPEUTICS INC (CNTX) will report earnings on 2026-03-12, after the market close.
CNTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CNTX. When comparing the yearly performance of all stocks, CNTX is one of the better performing stocks in the market, outperforming 88.7% of all stocks.
CNTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CNTX. CNTX has a great financial health rating, but its profitability evaluates not so good.
CNTX Financial Highlights
Over the last trailing twelve months CNTX reported a non-GAAP Earnings per Share(EPS) of -0.28. The EPS increased by 69.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.47% | ||
| ROE | -36.22% | ||
| Debt/Equity | 0 |
CNTX Forecast & Estimates
14 analysts have analysed CNTX and the average price target is 5.44 USD. This implies a price increase of 270.07% is expected in the next year compared to the current price of 1.47.